TD Cowen reiterates Edwards Lifesciences stock Buy rating on TAVR growth

The near-term setup is less about the quarter and more about whether reimbursement clarity converts into a durable volume inflection. If coverage expands the eligible pool, the first-order winner is Edwards because it already has the strongest procedural franchise and training footprint; the second-order winner is the hospital ecosystem, which gets more elective structural-heart volume, while smaller valve competitors face a harder time converting reps into share. That said, broader access also tends to normalize competition over time, so the biggest long-run gain may be industry procedure growth rather than permanent share capture.

Into earnings, the market is likely to punish any sign that share gains are being offset by higher clinical/SG&A investment or that the guidance raise is mostly optics. The key falsifier is not a slight EPS miss; it is a softer-than-expected procedural trajectory or any hint that the coverage memo stalls, narrows, or becomes operationally cumbersome. Near-term price reaction should be strongest if management confirms that Q3/Q4 cadence is accelerating rather than merely repeating the prior beat/reiterate pattern.

The consensus may be underestimating timing: reimbursement changes can pull forward demand from 2026 into late 2025, which can create a multi-quarter growth bump but also a later air pocket if backlog is depleted. That argues for a tactical rather than complacent bullish stance. Relative value matters too: if the market decides the policy change lifts the entire structural-heart category, Edwards’ premium multiple could compress even while fundamentals improve, which is why the cleanest expression may be versus a closer competitor rather than outright beta.